[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335948-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335948-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","multi-cohort-validation-of-ascore-an-anoikis-based-prognostic-signature-for-predicting-disease-progression-and-immunotherapy-response-in-bladder-cancer","Multi-cohort validation of Ascore - an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer","","Bladder cancer is the 10th most common cancer worldwide, and prognosis worsens with disease progression. Although immune checkpoint inhibitors (ICIs) benefit operable and advanced cases, selecting responders remains difficult. Anoikis, a specialized detachment-related form of cell death, is closely linked to tumor progression. This study develops anoikis-related biomarkers and uses consensus clustering to divide TCGA-BLCA patients into two ARG-driven clusters with distinct survival, clinical characteristics, tumor immune microenvironment, and predicted ICI responses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/multi-cohort-validation-of-ascore-an-anoikis-based-prognostic-signature-for-predicting-disease-progression-and-immunotherapy-response-in-bladder-cancer/335948/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/multi-cohort-validation-of-ascore-an-anoikis-based-prognostic-signature-for-predicting-disease-progression-and-immunotherapy-response-in-bladder-cancer/335948.png","ImageObject",300,407,{"name":42,"@type":43},"Patrick","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What challenge does the study address in bladder cancer treatment?","Question",{"text":63,"@type":64},"The study focuses on the difficulty of identifying which bladder cancer patients will respond favorably to immune checkpoint inhibitors (ICIs).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is Ascore and how is it derived?",{"text":68,"@type":64},"Ascore is a four-gene signature built to capture an anoikis-related gene expression pattern, developed after consensus clustering of anoikis-related genes in TCGA-BLCA.",{"name":70,"@type":61,"acceptedAnswer":71},"How was Ascore validated and what does it predict?",{"text":72,"@type":64},"Ascore was assessed in TCGA-BLCA, IMvigor210, and clinical cohorts using survival and immunotherapy response analyses, including circulating tumor cell detection and neoadjuvant anti-PD-1 treatment cohorts. It showed strong associations with survival and predictive capacity for immunotherapy response, outperforming PD-L1 in the reported clinical evaluation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335948,1790113423,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Xie etal. Molecular Cancer (2024) 23:30 [https://doi.org/10.1186/s12943-024-01945-9](https://doi.org/10.1186/s12943-024-01945-9)  \nMolecular Cancer  \n RESEARCH Open Access  \nMulti-cohort validation of Ascore: an anoikis-based prognostic signature  \nfor predicting disease progression  \nand immunotherapy response in bladder cancer  \nTianlei Xie1,2†, Shan Peng3†, Shujun Liu1†, Minghao Zheng4, Wenli Diao1, Meng Ding1, Yao Fu3, Hongqian Guo1*, Wei Zhao5* and Junlong Zhuang1,2*  \nAbstract  \nBladder cancer ranks as the 10th most common cancer worldwide, with deteriorating prognosis as the disease advances. While immune checkpoint inhibitors (ICIs) have shown promise in clinical therapy in both operable and advanced bladder cancer, identifying patients who will respond is challenging. Anoikis, a specialized form of cell death that occurs when cells detach from the extracellular matrix, is closely linked to tumor progression. Here, we aimed to explore the anoikis-based biomarkers for bladder cancer prognosis and immunotherapeutic decisions. Through consensus clustering, we categorized patients from theTCGA-BLCA cohort into two clusters based on anoikis-related genes (ARGs) . Significant differences in survival outcome, clinical features, tumor immune environment (TIME), and potential ICIs response were observed between clusters. We then formulated a four-gene signature, termed \"Ascore\", to encapsulate this gene expression pattern. The Ascore was found to be closely associated with survival outcome and served as an independent prognosticator in both theTCGA-BLCA cohort and the IMvigor210 cohort. It also demonstrated superior predictive capacity (AUC = 0 . 717) for bladder cancer immunotherapy response compared to biomarkers like TMB and PD-L1 . Finally, we evaluated Ascore’s independent prognostic performance as a non-invasive biomarker in our clinical cohort (Gulou-Cohort1) using circulating tumor cells detection, achieving an AUC of 0.803. Another clinical cohort (Gulou-Cohort2) consisted of 40 patients undergoing neoadjuvant anti-PD-1 treatment was also examined. Immunohistochemistry of Ascore in these patients revealed its correlation with the pathological response to bladder cancer immunotherapy (P = 0 . 004) . Impressively, Ascore (AUC = 0 . 913) surpassed PD-L1 (AUC = 0 . 662) in forecasting immunotherapy response and indicated better net benefit. In conclusion, our study introduces Ascore as a novel, robust prognostic biomarker for bladder cancer, offering a new tool for enhancing immunotherapy decisions and contributing to the tailored treatment approaches in this field. Keywords Bladder cancer, Prognostic signature, Immunotherapy, Anoikis, Tumor immune microenvironment  \n†Tianlei Xie, Shan Peng and Shujun Liu contributed equally to this work.  \n*Correspondence: Hongqian Guo [dr.ghq@nju.edu.cn](dr.ghq@nju.edu.cn)[ ](dr.ghq@nju.edu.cn)Wei Zhao [zw198626520@126.com](zw198626520@126.com)[ ](zw198626520@126.com)Junlong Zhuang [zhuangjl@njglyy.com](zhuangjl@njglyy.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licens","cbCaiqsqXOaXD0TJ","https://ap.wps.com/l/cbCaiqsqXOaXD0TJ","pdf",9584720,21,"English","# Introduction\n## Bladder cancer burden and treatment challenges\n## Immunotherapy advances and biomarker limitations\n# Abstract\n## Study aim and approach\n## Clustering results and prognostic performance\n## Clinical validation and predictive ability","[{\"question\":\"What challenge does the study address in bladder cancer treatment?\",\"answer\":\"The study focuses on the difficulty of identifying which bladder cancer patients will respond favorably to immune checkpoint inhibitors (ICIs).\"},{\"question\":\"What is Ascore and how is it derived?\",\"answer\":\"Ascore is a four-gene signature built to capture an anoikis-related gene expression pattern, developed after consensus clustering of anoikis-related genes in TCGA-BLCA.\"},{\"question\":\"How was Ascore validated and what does it predict?\",\"answer\":\"Ascore was assessed in TCGA-BLCA, IMvigor210, and clinical cohorts using survival and immunotherapy response analyses, including circulating tumor cell detection and neoadjuvant anti-PD-1 treatment cohorts. It showed strong associations with survival and predictive capacity for immunotherapy response, outperforming PD-L1 in the reported clinical evaluation.\"}]","Multi-cohort validation of Ascore - an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer | PDF",1790012899,53]